
ACADIA Pharmaceuticals Inc.
- Jurisdiction
United States - LEI
529900O3044NO0PEA039 - ISIN
US0042251084 (ACAD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€32.29 78.4% undervalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Read full profile
Fundamentals
- Net revenue
€869.06M - Gross margin
92.0% - EBIT
€201.99M - EBIT margin
23.2% - Net income
€189.49M - Net margin
21.8%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
GAROFALO ELIZABETH A. | N/A |
|
|
|
|
Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
|
|
|
|
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |